Skip to content
Screener

Syndax Pharmaceuticals SNDX Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$68.7MBeat by $4.4M
EPS-$0.78Miss by $0.20
Revenue estimate$64.3M
EPS estimate-$0.58

Next report

Nov 2, 2026 (in a month)
Revenue estimate$82.8M
EPS estimate-$0.51

Financials

Q4 2025

Income statement

See full
Revenue$68.7M+795%
Operating income-$62.5M+35.1%
Net income-$68.0M+27.8%
EPS (diluted)-$0.78+28.4%

Balance sheet

See full
Cash & equivalents$134.9M-12.4%
Total debt$351.5M-47.6%
Total equity$64.6M-77.6%
Total assets$529.7M-26.9%

Cash flow

See full
Operating cash flow-$69.5M-21.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.83B+61.8%
Enterprise value$2.04B+24.2%
P/S10.6×-37.1×

Profitability

See full
Operating margin-158.2%-74.5pp
Net margin-165.4%-77.3pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-161.8%-1,333pp
Debt / equity5.4×+3.1×
Current ratio4.4×-1.4×

FAQ

When did Syndax Pharmaceuticals report Q4 2025 earnings?
Syndax Pharmaceuticals (SNDX) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Syndax Pharmaceuticals's Q4 2025 revenue and EPS?
Syndax Pharmaceuticals reported revenue of $68.7M and eps of $-0.78 for Q4 2025.
Did Syndax Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $64.3M by $4.4M. EPS missed the consensus estimate of $-0.58 by $0.20.
How did Syndax Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 794.9% from $7.7M a year earlier and eps grew 29.1% from $-1.10.
Where can I find Syndax Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-076522) and the 10-K periodic report (0001193125-26-076536) directly on SEC EDGAR. The filing index links above go to sec.gov.